We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up.
- Authors
Wanschitz, Julia V.; Kaml, Manuela; Pfausler, Bettina; Helbok, Raimund; Wildner, Sophie; Widmann, Gerlig; Sahanic, Sabina; Deisenhammer, Florian; Löscher, Wolfgang N.; Reindl, Markus; Löffler-Ragg, Judith; Beer, Ronny
- Abstract
Regarding cardio-pulmonary health, the patient was followed within the prospective observational multicenter COVID study to investigate long-term sequelae in patients hospitalized for SARS-CoV-2 infection (NCT 04416100) that was approved by the local ethics committee (EK 1103/2020). Maintenance of standard immunosuppressive treatment is recommended in mild-to-moderate disease [[7]]; however, information about the management and outcome of patients with severe generalized MG treated with immune-depleting agents such as rituximab is still limited. Dear Sirs, Novel Corona Virus Disease 2019 (COVID-19) poses an unpredictable risk for patients with myasthenia gravis (MG) due to potentially additive effects of bulbar and respiratory muscle weakness and viral lung affection [[1]].
- Subjects
MYASTHENIA gravis; SARS-CoV-2; VIRUS diseases; MEDICAL ethics; COVID-19; RESPIRATORY infections
- Publication
Journal of Neurology, 2021, Vol 268, Issue 8, p2700
- ISSN
0340-5354
- Publication type
Letter
- DOI
10.1007/s00415-020-10310-x